Mergers and acquisitions have never been seen in the pharmaceutical industry. In the past 10 years, Pfizer has successively annexed Warner Lambert and Pharmacia to the marriage of Glaxo Wellcome and Shi Ke Bicheng, or the French Sanofi company to eat like a snake. Aventis, the company's business scale is getting bigger and bigger, and the ultra-large "big Mac" enterprise is also born. However, in recent years, the industry's unfavorable years have made the acquisition targets of pharmaceutical companies begin to change. More companies have begun to seek opportunities to enhance their R&D capabilities from mergers and acquisitions, or to use beneficial mergers and acquisitions to penetrate new market segments. Among them.
According to statistics, in the first half of 2008, there were 19 large-scale mergers and acquisitions cases in the world, with a total value of 22.7 billion US dollars. As a result, the number of pharmaceutical mergers in 2008 is expected to reach or approach the level of 44 in 2007, but the overall turnover may be a far cry from the $79.5 billion in 2007.
Of the 19 transactions, only 6 cases exceeded $1 billion, and Zui’s figure was that Japan’s Takeda Corporation acquired the Millennium Company of the United States for $8.8 billion. In fact, in 2008, Japanese companies expanded overseas and blew the year of acquiring the horn of European and American companies. In the 10 transactions with a high amount of Zui, 5 buyers from Japan were from Japan, which strengthened the share of these Japanese companies in the overseas market.
Due to the global economic downturn and the uncertainties brought about by the impact of the US election on future US medical care, the pace of pharmaceutical mergers and acquisitions may slow down during the rest of 2008, and Zui will also significantly increase the total amount of mergers and acquisitions. It is behind the nearly five-year average of $66.5 billion.
However, the acquisition of biotechnology is still very popular, especially the large pharmaceutical giants urgently need new products with market potential to fill the gap in their research and development lines. Since the total value of the 10 mergers and acquisitions of biotechnology in the pharmaceutical industry in the first half of this year has reached 3.11 billion US dollars, the total transaction volume of the whole year is expected to reach or exceed the 4.357 billion US dollars in 2007.
Undoubtedly, the suspense of this year's bio-merger Zui is still the story of Roche's full acquisition of Genentech's shares, the total value of this acquisition will be as high as 55 billion US dollars. However, with the insistence of those minority shareholders, it seems that it is not an easy task for Roche to win its goal with the initial offer of Zui.
According to statistics, in the first half of 2008, there were 19 large-scale mergers and acquisitions cases in the world, with a total value of 22.7 billion US dollars. As a result, the number of pharmaceutical mergers in 2008 is expected to reach or approach the level of 44 in 2007, but the overall turnover may be a far cry from the $79.5 billion in 2007.
Of the 19 transactions, only 6 cases exceeded $1 billion, and Zui’s figure was that Japan’s Takeda Corporation acquired the Millennium Company of the United States for $8.8 billion. In fact, in 2008, Japanese companies expanded overseas and blew the year of acquiring the horn of European and American companies. In the 10 transactions with a high amount of Zui, 5 buyers from Japan were from Japan, which strengthened the share of these Japanese companies in the overseas market.
Due to the global economic downturn and the uncertainties brought about by the impact of the US election on future US medical care, the pace of pharmaceutical mergers and acquisitions may slow down during the rest of 2008, and Zui will also significantly increase the total amount of mergers and acquisitions. It is behind the nearly five-year average of $66.5 billion.
However, the acquisition of biotechnology is still very popular, especially the large pharmaceutical giants urgently need new products with market potential to fill the gap in their research and development lines. Since the total value of the 10 mergers and acquisitions of biotechnology in the pharmaceutical industry in the first half of this year has reached 3.11 billion US dollars, the total transaction volume of the whole year is expected to reach or exceed the 4.357 billion US dollars in 2007.
Undoubtedly, the suspense of this year's bio-merger Zui is still the story of Roche's full acquisition of Genentech's shares, the total value of this acquisition will be as high as 55 billion US dollars. However, with the insistence of those minority shareholders, it seems that it is not an easy task for Roche to win its goal with the initial offer of Zui.
Hospital/Clinic/Drugstore Equipment
Lightweight Wheelchair,Folding Wheelchair,Manual Wheelchair,Portable Wheelchair
Surgimed Medical Supplies Co.,Ltd , https://www.surgimedcn.com